About TAXUS CARDIUM PHARMACEUTICALS GROUP
Sector
Industry
CEO
Christopher J. Reinhard
Website
Headquarters
San Diego
Founded
2003
ISIN
US8767671048
FIGI
BBG000LYKLW7
Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company. The company focuses on the late-stage clinical and development of regenerative medicine therapeutics. Its product candidates include Generx, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of cardiac microvascular insufficiency due to increasing coronary artery disease, and Excellagen, an acellular biological skin substitute designed as a wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers. The company was founded by Christopher J. Reinhard and Tyler M. Dylan-Hyde in December 2003 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CRXM is 0.000001 USD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange TAXUS CARDIUM PHARMACEUTICALS GROUP stocks are traded under the ticker CRXM.
TAXUS CARDIUM PHARMACEUTICALS GROUP is going to release the next earnings report on Jun 20, 2024. Keep track of upcoming events with our Earnings Calendar.
Yes, you can track TAXUS CARDIUM PHARMACEUTICALS GROUP financials in yearly and quarterly reports right on TradingView.
Like other stocks, CRXM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TAXUS CARDIUM PHARMACEUTICALS GROUP stock right from TradingView charts — choose your broker and connect to your account.